Please Wait...

Klause Engelke

Translation skills

Main profile

Klaus Engelke, PhD.
Director of Special Imaging Techniques

Professor Klaus Engelke received a Ph.D. in Physics from the University of Hamburg, Germany for his pioneering work on µCT using Synchrotron Radiation. Afterwards he joined the Osteoporosis Research Group at UCSF (University of California at San Francisco) to develop advanced radiographic methods for the diagnosis of osteoporosis. At UCSF he also developed the first workstation for vertebral fracture analysis using digitized x-rays. He then joined the newly formed Institute of Medical Physics (IMP) at the University of Erlangen, Germany to develop desktop µCT Scanners and advanced image processing methods. Prof. Engelke joined Synarc, now Bioclinica, as a Director of Special Imaging Techniques in 2005. At the University of Erlangen he continues to develop novel in vivo and in vitro image acquisition and analysis techniques for the musculoskeletal field. He has authored more than 100 peer reviewed publications and more than 200 conference contributions. In 2007 he chaired the QCT Task Force that developed the official positions of the International Society of Clinical Densitometry (ISCD) and is member of the committee that developed the German guidelines for the diagnosis and treatment of osteoporosis. In 2017 he was awarded the Dr. John P. Bilezikian Global Leadership Award from the International Society for Clinical Densitometry, which recognizes Klaus for his contributions to the advancement of osteoporosis and bone imaging research. He is also a member of the scientific advisory committee of the International Osteoporosis Foundation and co-chaired the Committee on Bone Densitometry of the International Commission on Radiation Units (ICRU).

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (3 days ago)
#Pharma & CROs: Ck it out! Enterprise tools for site payments automation & reconciliation. https://t.co/LFri5Kv0WC
bioclinica (3 days ago)
Can having a geographically diverse network of high performing sites mean fewer sites are needed in a trial? Can ha… https://t.co/tZYvWrNzHg
bioclinica (3 days ago)
Confidence is a good thing ─ especially in the clinical supply chain for global clinical trials. Here’s how accurat… https://t.co/70VwXCwuWw
bioclinica (4 days ago)
#Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most… https://t.co/3YNpB9hTXs
bioclinica (1 week ago)
Announcing our new Chief of Staff @bioclinica Adrienne Rossi! Also welcoming President Bioclinica Site Network Eliz… https://t.co/toB9yk534k
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen